Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms

• Egile Nagusiak: Mikhail Kostinov (Egilea), Oksana Svitich (Egilea), Alexander Chuchalin (Egilea), Natalya Abramova (Egilea), Valery Osiptsov (Egilea), Ekaterina Khromova (Egilea), Dmitry Pakhomov (Egilea), Vitaly Tatevosov (Egilea), Anna Vlasenko (Egilea), Vilia Gainitdinova (Egilea), Kirill Mashilov (Egilea), Nadezhda Kryukova (Egilea), Irina Baranova (Egilea), Anton Kostinov (Egilea)
• Formatua: Liburua
• Argitaratua: BioExcel Publishing Ltd, 2023-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Although extensive research has been conducted on the role of local immunity in patients with SARS-CoV-2, little is known about the production and concentrations of secretory IgA (SIgA) in different mucosal compartments. This article aims to assess the secretion of SIgA in the nasal and...